Over the last 20 years, the idea of “designing biology” has gone from science fiction to just science, as the field of synthetic biology has exploded, with applications from therapeutics to manufacturing and more.  In this episode from January 2019, one of the pioneers in the field, professor James J. Collins of MIT, joins a16z general partner on the Bio + Health fund, Vijay Pande, and editorial partner Hanne Winarsky, to discuss the origins of synthetic biology or "synbio", to what "engineering and designing" biology really looks like in action and the disciplinary differences between how biologists and engineers see the world.

In this episode from October 2019, People.AI founder and CEO Oleg Rogynskyy and a16z partner Peter Lauten discuss with Das Rush about what the rise of AI in B2B means for enterprises, workers, and startups. They explain why AI provides a strong first mover advantage to enterprises that adopt it early; how it can automate lower level tasks, maximize our focus, and, ultimately, make our work more meaningful; and for startups, they provide a playbook for seizing the next AI opportunity. To learn more about the latest in AI, ML, data, and how enterprise are working with these technologies, go to future.com/data.